| Literature DB >> 16439122 |
Robert M Garbaccio1, Mark E Fraley, Edward S Tasber, Christy M Olson, William F Hoffman, Kenneth L Arrington, Maricel Torrent, Carolyn A Buser, Eileen S Walsh, Kelly Hamilton, Michael D Schaber, Christine Fernandes, Robert B Lobell, Weikang Tao, Vicki J South, Youwei Yan, Lawrence C Kuo, Thomayant Prueksaritanont, Donald E Slaughter, Cathy Shu, David C Heimbrook, Nancy E Kohl, Hans E Huber, George D Hartman.
Abstract
2,4-Diaryl-2,5-dihydropyrroles have been discovered to be novel, potent and water-soluble inhibitors of KSP, an emerging therapeutic target for the treatment of cancer. A potential concern for these basic KSP inhibitors (1 and 2) was hERG binding that can be minimized by incorporation of a potency-enhancing C2 phenol combined with neutral N1 side chains. Aqueous solubility was restored to these, and other, non-basic inhibitors, through a phosphate prodrug strategy.Entities:
Mesh:
Substances:
Year: 2006 PMID: 16439122 DOI: 10.1016/j.bmcl.2005.12.094
Source DB: PubMed Journal: Bioorg Med Chem Lett ISSN: 0960-894X Impact factor: 2.823